Unapproved malaria drugs may boost resistance
The growing use of unapproved, sub-standard versions of anti-malaria medicines in Africa and Asia risks spreading drug resistance, the World Health Organisation (WHO) has warned.
Robert Newman, head of the global malaria programme at the WHO, claimed on Thursday, 22 April 2010, that the continued use of artemisinin monotherapies - which do not combine it with a second drug to limit the risk of developing resistance - poses a threat to millions of people.
Newman said that despite a 2007 resolution to outlaw monotherapies, 29 Asian and African countries still authorise this treatment to be sold in pharmacies. Researchers have linked the recent emergence of malaria strains resistant to artemisinin combination therapy (ACT) in south east Asia to the use of monotherapies and sub-standard drugs. The WHO estimates that malaria kills nearly one million people every year.
Source: Panos London
Panos London promotes the participation of poor and marginalised people in national and international development debates through media and communication projects. It is part of the worldwide Panos Network of independent institutes working to ensure that information is used more effectively to foster debate, pluralism and democracy.
Go to: http://www.panos.org.uk
